AffiliationDepartment of Neurology and Neuroscience, Beaumont Hospital and Royal College of Surgeons in Ireland, Dublin 9, Ireland.
Magnetic Resonance Imaging
Protein Tyrosine Phosphatases, Non-Receptor
MetadataShow full item record
CitationLafora disease: epidemiology, pathophysiology and management. 2010, 24 (7):549-61 CNS Drugs
AbstractLafora disease is a rare, fatal, autosomal recessive, progressive myoclonic epilepsy. It may also be considered as a disorder of carbohydrate metabolism because of the formation of polyglucosan inclusion bodies in neural and other tissues due to abnormalities of the proteins laforin or malin. The condition is characterized by epilepsy, myoclonus and dementia. Diagnostic findings on MRI and neurophysiological testing are not definitive and biopsy or genetic studies may be required. Therapy in Lafora disease is currently limited to symptomatic management of the epilepsy, myoclonus and intercurrent complications. With a greater understanding of the pathophysiological processes involved, there is justified hope for future therapies.
- Lafora progressive myoclonus epilepsy: recent insights into cell degeneration.
- Authors: Spuch C, Ortolano S, Navarro C
- Issue date: 2012 May
- Advances in lafora progressive myoclonus epilepsy.
- Authors: Delgado-Escueta AV
- Issue date: 2007 Sep
- [Lafora's disease presenting with progressive myoclonus epilepsy].
- Authors: Béjot Y, Lemesle-Martin M, Contégal F, Graule-Petot A, Thauvin C, Aubriot-Lorton MH, Moreau T, Giroud M
- Issue date: 2007 Oct
- [Myoclonic epilepsy of Lafora: a case report].
- Authors: Rudenskaia GE, Zakharova EIu, Karpin SL, Uchaev DA
- Issue date: 2010
- Three patients with lafora disease: different clinical presentations and a novel mutation.
- Authors: Poyrazoğlu HG, Karaca E, Per H, Gümüs H, Onay H, Canpolat M, Canöz Ö, Ozkınay F, Kumandas S
- Issue date: 2015 May